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The Cytomegalovirus protein 
pUL37×1 targets mitochondria to 
mediate neuroprotection
Chien Tai Hong1,2,3,*, Kai-Yin Chau1,* & Anthony H. V. Schapira1
There is substantial evidence that mitochondrial dysfunction plays a significant role in the 
pathogenesis of Parkinson disease (PD). This contribution probably encompasses defects of oxidative 
phosphorylation, mitochondrial turnover (mitophagy), mitochondrial derived oxidative stress, 
and apoptotic signalling. Human cytomegalovirus immediate-early protein pUL37 × 1 induces Bax 
mitochondrial translocation and inactivation to prevent apoptosis. Over-expressing pUL37 × 1 in 
neuronal cells protects against staurosporin and 6-hydroxydopamine induced apoptosis and cell 
death. Protection is not enhanced by bax silencing in pUL37 × 1 over-expressing cells, suggesting 
a bax-dependent mechanism of action. pUL37 × 1 increases glycolysis and induces mitochondrial 
hyperpolarization, a bax independent anti-apoptotic action. pUL37 × 1 increases glycolysis through 
activation of phosphofructokinase by a calcium-dependent pathway. The dual anti-apoptotic 
mechanism of pUL37 × 1 may be considered a novel neuroprotective strategy in diseases where 
mitochondrial dysfunction and apoptotic pathways are involved.
Mitochondrial dysfunction is thought to play an important role in the pathogenesis of Parkinson disease (PD) 
(review by Schapira)1. This includes the mitochondrion’s role in oxidative phosphorylation, free radical genera-
tion, triggering apoptosis and alteration of mitochondrial turnover (mitophagy). The mitochondrion therefore 
presents multiple pathways for which to target interventions that could prevent or reverse the deficits and poten-
tially favourably influence the course of PD.
Many viruses, including human cytomegalovirus (CMV), encode proteins that inhibit apoptosis, a powerful 
innate defence mechanism against viral infection2,3. UL37 exon 1 protein (pUL37 × 1), which is also known 
as a viral mitochondria-localized inhibitor of apoptosis, is encoded by the immediate early ul37 × 1 gene4. 
pUL37 × 1 inactivates Bax and inhibits apoptosis by causing the mitochondrial translocation and conformational 
change of Bax5–7. The Bax-binding function of pUL37 × 1 is essential for the apoptosis prevention, survival of 
the host cell and replication of the virus. Cells in which the bax gene has been silenced are not protected from 
staurosporin-induced apoptosis.
The anti-apoptotic action of pUL37 × 1 therefore offers a unique and novel mechanism for neuroprotection. 
We now demonstrate that pUL37 × 1 over-expression protected against toxin-induced cell death and apoptosis 
in PD cellular models. pUL37 × 1 over-expression protected against cell death and although Bax translocated to 
mitochondria, apoptosis was prevented. In addition, pUL37 × 1 over-expression also increased cellular glycolysis 
and hyperpolarized mitochondria, actions which contributed to the neuroprotective mechanism of pUL37 × 1 
in these models.
Results
Generation and Characterization of Three pUL37 × 1 Over-expressing SH-SY5Y Cell Lines. In 
order to evaluate the neuroprotective potential of pUL37 × 1 over-expression, pul37 × 1 cDNA fused with a 3′ 
haemagluttinin (HA) epitope was cloned into pcDNA3.1 plasmid and transfected into SH-SY5Y cells. Three inde-
pendent stable over-expressing lines, named as pUL37 × 1-1 to 3 in the following paragraphs were obtained upon 
geneticin selection. Control lines used in this study included SH-SY5Y cells (labelled as control-1), SH-SY5Y cells 
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over-expressing dsRed in the mitochondria (control-2) and SH-SY5Y cells with pcDNA3.1(+) plasmid (con-
trol-3). Data which were labelled as control and pUL37 × 1 were the combination of each cell line except where 
specified.
The representative Western blot image confirmed that the selected over-expressing cell lines expressed 
pUL37 × 1-HA by producing a distinctive band of size equivalent to the calculated molecular weight of 55.3 kDa 
detected by anti-HA antibody (Fig. 1A), which was absent from the three different control lines. pUL37 × 1-1 
expressed the most pUL37 × 1 followed by pUL37 × 1–2 and pUL37 × 1-3 (Fig. 1B). The purity of ectopic expres-
sion in each line was confirmed by immunocytochemistry, which showed that most of the cells in pUL37 × 1 
over-expressing lines exhibited positive pUL37 × 1-HA staining (Fig. 1C). Immunocytochemistry and confo-
cal microscopy confirmed a substantial mitochondrial localization of pUL37 × 1 (Fig. 1D). pUL37 × 1-HA was 
detected by anti-HA.
pUL37 × 1 Over-expression Protected Against Toxin-Induced Apoptosis and Cell Death. 
Cytochrome c, an electron carrier between complex III and IV, is also known to induce apoptosis when it is 
released into the cytoplasm. pUL37 × 1 over-expression significantly prevented the release of cytochrome c 
from mitochondria to cytoplasm. Staurosporine is a protein kinase C inhibitor and apoptosis inducer; 500 nM 
treatment for 3 hours caused increased cytochrome c release in the control which was blocked in pUL37 × 1 
over-expressing cells (Fig. 2A). In addition, pUL37 × 1 over-expression significantly reduced the cytosolic 
cytochrome c in the absence of toxin.
The activation of caspase-3 is an important component of the apoptosis pathway. pUL37 × 1 over-expression 
was expected to prevent the activation of caspase-3 due to blocking of the upstream apoptosis process. In 
the absence of toxin, pUL37 × 1 over-expression did not affect the activity of caspase-3 compared to control. 
However, following 500 nM staurosporine treatment for 4 hours, pUL37 × 1 over-expressing SH-SY5Y cells 
exhibited significantly lower caspase-3 activity compared to control (Fig. 2B). Based on these findings, pUL37 × 1 
over-expression is able to block the apoptosis cascade induced by staurosporine.
pUL37 × 1 over-expression also protected against cell death induced by staurosporin and 6-hydroxydopamine 
(6-OHDA). 6-OHDA is an oxidative stress inducer and widely-used in PD in vivo and in vitro models8. Stable 
Figure 1. Generation and characterization of stable pUL37 × 1 over-expressing SH-SY5Y cell lines. 
(A) Three independent pUL37 × 1 over-expressing SH-SY5Y cell lines were generated and analyzed for this 
study. Representative Western blot image demonstrates the expression of pUL37 × 1-HA. pUL37 × 1-HA was 
detected by anti-HA antibody. Control- line 1 was normal SH-SY5Y cells; control-line 2 was SH-SY5Y cell over-
expressing dsRed-Mito and control-line 3 was SH-SY5Y cells with the empty vector, pcDNA3.1(+). β-actin 
was loading control. (B) Densitometry analysis of pUL37 × 1 expression level: pUL37 × 1 line-1 expressed the 
most (192.2 ± 27.7%), followed by line-2(155.4 ± 9.2%) and line-3 (100 ± 0%)(n = 6). The expression level was 
normalized by line-3 and corrected by β-actin. Data were presented as mean ± S.E.M. The experiments had 
been repeated for three times. (C) All three over-expressing lines homogenously expressed pUL37 × 1-HA 
which was detected by immunocytochemistry whereas the control SH-SY5Y cells did not express detectable 
pUL37 × 1-HA (green: pUL37 × 1-HA, blue: DAPI). pUL37 × 1-HA was detected by anti-HA antibody. (D) The 
mitochondrial localization of pUL37 × 1. In the representative image, mitochondria were labelled by TOM20 
(red) and pUL37 × 1-HA was detected by anti-HA antibody (green). In the merged image, a substantial co-
localization is demonstrated (yellow).
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pUL37 × 1 over-expressing cell lines did not show increased spontaneous cell death compared to control, as 
determined by LDH release (Fig. 2C). pUL37 × 1 over-expression significantly reduced the cell death induced 
by 30 nM staurosporin treatment for 24 hours and 15 nM staurosporin treatment for 24 or 48 hours (Fig. 2C,D). 
Moreover, pUL37 × 1 over-expression also protected against 60 μM 6-OHDA treatment for 24 hours and 30 μM 
6-OHDA for 48 and 72 hours treatment (Fig. 2E,F). Similar effects were observed using propidium iodide (PI) 
staining assay (Supplement, S1). The levels of protection were similar in all three pUL37 over-expressing lines 
(Supplement, S2).
pUL37 × 1 Over-expression Protected against Apoptosis and Neuronal Death in Rat Primary 
Cortical Cultures. Primary rat cortical cultures were used to investigate further the protection conferred by 
pUL37 × 1 over-expression. Liposomal transfecting reagent mixed with red fluorescence protein (RFP) plasmid 
(control) or a mixture of pUL37 × 1 and RFP plasmids at 10 to 1 ratio (experiment) were co-incubated with the 
cultures for 48 hours. pUL37 × 1 over-expression was identified by the expression of RFP.
The anti-apoptotic effect of pUL37 × 1 over-expression on primary rat cortical culture was detected by the 
antibody against cleaved caspase-3, which is the activated form of caspase-3. As expected, 6-OHDA treatment 
Figure 2. pUL37 × 1 over-expression protected against toxin-Induced apoptosis and cell death in SH-
SY5Y cells. (A) pUL37 × 1 over-expression significantly reduced cytosolic cytochrome c upon 500 nM 
staurosporine treatment for 3 hours (0.46 ± 0.05 ng/mg cell lysate in control versus 0.21 ± 0.03 ng/mg cell 
lysate in pUL37 × 1 over-expression lines, p < 0.01, n = 3). (B) pUL37 × 1 over-expression did not alter the 
baseline caspase-3 activity (set as 100%) but significantly lowered the increase of caspase-3 activity upon 
500 nM staurosporine treated for 4 hours (1156.5 ± 137.2% in control versus 440.5 ± 56.3% in pUL37 × 1 
over-expression, p < 0.001, n = 5). (C) pUL37 × 1 over-expression did not increase spontaneous cell death 
compared with control. pUL37 × 1 over-expression significantly protected cell death upon either 15 or 30 nM 
staurosporine (STS) treatment for 24 hours (15 nM: 25.4 ± 2.3% in control, 13.9 ± 0.8% in pUL37 × 1 over-
expression, p < 0.01, n = 4; 30 nM: 22.3 ± 1.3% in control, 13.7 ± 0.5% in pUL37 × 1 over-expression, p < 0.001, 
n = 8). (D) pUL37 × 1 over-expression significantly reduced the percentage of LDH release induced by 15 nM 
staurosporine treatment for 24 and 48 hours (24 hours: 25.4 ± 2.3% in control, 13.9 ± 0.8% in pUL37 × 1 
over-expression, p < 0.01, n = 4; 48 hours: 22.8 ± 1.5% in control, 15.1 ± 1.9% in pUL37 × 1 over-expression, 
p < 0.01, n = 6). (E) pUL37 × 1 over-expression significantly decreased the percentage of LDH release induced 
by 60 μM 6-OHDA treatment for 24 hours (30.6 ± 1.9% in control, 12.9 ± 0.6% in pUL37 × 1 over-expression, 
p < 0.001, n = 6). (F) pUL37 × 1 over-expression significantly decreased the percentage of LDH release induced 
by 30 μM 6-OHDA treatment for 48 and 72 hours (48 hours: 22.8 ± 1.5% in control, 15.1 ± 1.9% in pUL37 × 1 
over-expression, p < 0.01, n = 8; 72 hours: 30.2 ± 1.3% in control, 15.1 ± 0.6% in pUL37 × 1 over-expression, 
p < 0.001, n = 6). Data were presented as mean ± S.E.M. Statistics was performed by two-tailed Student’s t- test. 
The n numbers represented the experimental repeat of each pUL37 × 1 over-expressing and control lines (NS, 
non-significant, *p < 0.05, **p < 0.01; ***p < 0.001).
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resulted in a significant increase in apoptosis in cortical neurons. pUL37 × 1 over-expression alone did not 
increase apoptosis compared to control. However, following 20 μM 6-OHDA treatment for 6 hours, pUL37 × 1 
over-expression significantly reduced the percentage of apoptotic cells(Fig. 3A,B). Similar results were obtained 
using Fluoro-Jade C (FJ-C), as a specific marker for degenerative neurons. pUL37 × 1 over-expression signifi-
cantly reduced the neuronal death labelled by FJ-C compared with control following 10 μM 6-OHDA treatment 
for 24 hours (Fig. 3C,D). The transfection efficiency was approximately 5%.
Figure 3. pUL37 × 1 over-expression protected against apoptosis and neuronal death in rat primary 
cortical culture. (A) The representative images of apoptotic cell counting by positive cleaved caspase-3 stain 
(green) on RFP and pUL37 × 1 transfecting rat primary cortical culture. Because the ratio of concentration 
between pUL37 × 1 and RFP is 10:1, expression of RFP (red) is assumed as pUL37 × 1 expressing neurons. 
The apoptotic neurons were identified based on the RFP-expressed cells with positive cleaved caspase-3 stain 
(arrowhead) whereas RFP-expressed cells without cleaved caspase-3 stain were recognized as survival neurons. 
Low magnification images (left) were used to evaluate incidents of apoptosis whereas high magnification 
images (right, corresponding to the boxed area in the low magnification images) show the representative 
immunoreactivity of cleaved caspase-3 on transfected neurons. For each rat cortical culture preparation, at 
least ten low magnification images were taken to quantitative analysis. (B) pUL37 × 1 expression significantly 
reduced the percentage of apoptotic cells induced by 20 μM 6-OHDA treatment for 6 hours compared with RFP 
expressing ones (21.8 ± 1.6% in RFP-control versus 13.3 ± 2.1% in pUL37 × 1 over-expression, p < 0.05, n = 6). 
(C) The representative images of fluoro-jade C (FJ-C) stain. Similar to the detection of apoptotic neurons, RFP-
expressed neurons (red) with positive FJ-C stain (green, double arrowhead) were counted as death neurons 
whereas RFP-expression only neurons were survival neurons. Low magnification images (left) were used for 
counting dead neurons whereas high magnification images (right, corresponding to the boxed area in the low 
magnification images) show the representative fluorescent FJ-C staining. (D) pUL37 × 1 expression significantly 
reduced the percentage of FJ-C positive neurons induced by 10 μM 6-OHDA treatment for 24 hours compared 
with RFP expressing ones (25.3 ± 1.9% in RFP-control versus 17.4 ± 2.7% in pUL37 × 1 over-expression, 
p < 0.05, n = 6). Data were presented as mean ± S.E.M. Statistics was performed by two-tailed Student’s t- test. 
(NS, non-significant, *p < 0.05 ).
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The protection of pUL37 × 1 is Bax-dependent. The mitochondrial sequestration and inactivation 
of Bax has been postulated as an anti-apoptotic mechanism of pUL37 × 15–7. In the present study, pUL37 × 1 
over-expressing cells exhibited some co-localization of Bax with mitochondria, supporting a mitochondrial trans-
location of Bax (Supplement S3A).
To investigate this protective mechanism further, both control and pUL37 × 1 over-expressing cells were 
treated with either scrambled siRNA or bax siRNA for 3 days. bax siRNA silencing substantially reduced the 
expression of Bax compared with scrambled siRNA (Supplement S3B). Following challenge with 30 nM stauros-
porin for 24 hours, bax siRNA silencing reduced the percentage of LDH release compared with scrambled siRNA 
silencing in control cells. In the presence of scrambled siRNA silencing, pUL37 × 1 over-expression remained 
protective against staurosporin. However, the combination of bax siRNA silencing with pUL37 × 1 did not mod-
ify LDH release (Fig. 4). These data indicate that the anti-apoptotic effect of pUL37 × 1 over-expression was 
dependent on Bax activity.
Glycolysis-induced Mitochondrial Hyperpolarization as a Protective Mechanism of 
pUL37 × 1. Mitochondrial membrane depolarization is a common phenomenon during apoptosis9, and has 
been reported to take place before Bax translocation10. Hyperpolarization of mitochondria has been shown to be 
a protective strategy11. pUL37 × 1 over-expression induced hyperpolarization of mitochondria in SH-SY5Y cells 
(Fig. 5A,B). This hyperpolarization was reduced but was still significantly above control following exposure to 
6-OHDA (Fig. 5C).
Mitochondrial hyperpolarization can result from complex V inhibition, insufficient ADP supply or increased 
glycolysis12. However, the two former result in energy deficit and lead to cell death, which did not occur at base-
line in pUL37 × 1 over-expression (Fig. 5C). CMV infection has been found to increase glycolysis in host cells. 
pUL37 × 1 over-expression significantly increased glycolysis measured by the XF analyser compared with con-
trol in SH-SY5Y cells (Fig. 5D). This glycolysis-enhancing effect did not result from oxidative phosphorylation 
(OXPHOS) inhibition as there was neither significant difference in oxygen consumption rate (OCR) between 
control and pUL37 × 1 over-expressing SH-SY5Y cells (Fig. 5D), nor reduced ADP phosphorylation and enzy-
matic activity from each mitochondrial respiratory chain complex (Supplement S4).
Glycolytic inhibitors, either 2-deoxyglucose (2DG) and 3-bromopyruvate (3BP) were applied to pUL37 × 1 
over-expressing SH-SY5Y cells to verify glycolysis-dependent mitochondrial hyperpolarization. In control 
SH-SY5Y cells, neither 10 μM 2DG nor 5 μM 3BP altered the mitochondrial membrane potential. However, 
the hyperpolarization induced by pUL37 × 1 over-expression dissipated following treatment with either 2DG 
or 3BP (Fig. 5E). This result confirmed that the mitochondrial hyperpolarization associated with pUL37 × 1 
over-expression was dependent on its glycolysis-enhancing effect.
To determine whether the glycolytic-dependent mitochondrial hyperpolarization contributes to the protective 
effect of pUL37 × 1 we assessed the effect of glycolysis inhibition with toxin exposure. Both 10 μM 2DG and 5 μM 
3BP attenuated but did not prevent the protective effect of pUL37 × 1 over-expression against 6-OHDA (Fig. 5F).
pUL37 × 1 over-expression Increased Glycolysis is Calcium Dependent. The rate of glycolysis is 
normally tightly controlled by three enzymes: hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase 
(PK). Increased glycolytic metabolites and flux in host cells have been noted during CMV infection13,14. In the 
present study, there was no significant difference in the expression levels of these proteins between control and 
pUL37 × 1 over-expressing cells (Fig. 6A,B). However, pUL37 × 1 over-expression up-regulated PFK enzymatic 
activity (Fig. 6C). This suggests that pUL37 × 1 modulates glycolysis through a post-translational mechanism.
Figure 4. The protection of pUL37 × 1 over-expression resulted from the Bax inactivation. 5 nM bax 
siRNA silencing for 3 days significantly reduced LDH release upon 30 nM staurosporine treated for 24 hours 
(20.94 ± 1.35% in scramble siRNA versus 16.19 ± 1.09% in bax siNRA, p < 0.01, n = 8). However, this reduction 
did not present in pUL37 × 1 over-expressing SH-SY5Y cell. In addition, there was no significant difference of 
LDH release upon 30 nM staurosporine treated for 24 hours between controls with pUL37 × 1 over-expressing 
SH-SY5Y cells when both of them underwent 5 nM bax siRNA silencing. Data were presented as mean ± S.E.M. 
Statistics was performed by two-tailed Student’s t- test. The n number represented the experimental repeat 
from each pUL37 × 1 over-expression lines and control (include normal SH-SY5Y cells, over-expressing 
dsRed-mito SH-SY5Y cells and over-expressing pcDNA Zero SH-SY5Y cells) (NS, non-significant, **p < 0.01; 
***p < 0.001).
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The activity of PFK is tightly regulated by intracellular calcium levels: high intracellular calcium triggers the 
binding of calmodulin with PFK with formation of the activated dimer of the enzyme15. pUL37 × 1 is known 
to cause the release of calcium from endoplasmic reticulum (ER)16, which may account for the enhanced PFK 
activity and increased glycolysis. The present study demonstrated that pUL37 × 1 over-expression increased 
both intracellular calcium (measure by Fluo-4) and mitochondrial calcium (measure by Rhod-2) (Fig. 6D). The 
increase of both intracellular and mitochondrial calcium indicated the release of calcium from ER. In order 
to establish the relationship between glycolysis and intracellular calcium level, BAPTA-AM, a cell permeable 
calcium caging agent was used to investigate the causal effect. After 30 nM BAPTA-AM treatment for 50 minutes, 
glycolytic activity was significantly reduced in pUL37 × 1 over-expression cells compared with baseline, with 
no change in control cells (Fig. 6E). These results indicate that pUL37 × 1 up-regulates glycolysis through a 
calcium-dependent pathway to activate PFK.
Figure 5. The protection of pUL37 × 1 over-expression is mediated by mitochondrial hyperpolarization 
and glycolysis. (A,B) The representative images of TMRM staining from control (A) and pUL37 × 1 over-
expressing cell (B). pUL37 × 1 over-expressing cell exhibits higher TMRM staining comparing with control. 
Both control and pUL37 × 1 over-expressing cells were assessed under identical condition, exposure time 
and intensity gain (C) The fluorescence intensity of TMRM was calculated by ImageJ with adjustment of 
mitochondrial content. pUL37 × 1 over-expression significantly hyperpolarized baseline mitochondrial 
membrane potential (175.3 ± 7.4% compared with 100.0 ± 1.4% from control, p < 0.001, n = 24 from 
control SH-SY5Y cells and n = 8 from each pUL37 × 1 over-expressing line) and rescued the mitochondrial 
depolarization induced by 100 μM 6-OHDA treatment for 1 hour (114.1 ± 3.2% compared with 77.0 ± 2.4% 
from control, p < 0.001, n = 10 from control SH-SY5Y cells and n = 5 from each pUL37 × 1 over-expressing 
line). (D) pUL37 × 1 over-expression induced a significant increase of extracellular acidification rate (ECAR) 
compared with control (pUL37 × 1: 2.68 ± 0.46, control: 1.39 ± 0.20 pH/min/μg, p < 0.05, n = 10) without 
impaired oxidative phosphorylation as measure by oxygen consumption rate (OCR). (E) Glycolytic inhibitors, 
either 10 μM 2-deoxy-glucose (2DG) or 5 μM 3-Bromopyruvate (3BP), significantly reversed the phenomenon 
of mitochondrial hyperpolarization resulted from pUL37 × 1 over-expression ( pUL37 × 1: 163.6 ± 9.3%, 
pUL37 × 1 + 10 μM 2DG: 103.7 ± 1.9%, pUL37 × 1 + 5 μM 3BP: 87.8 ± 2.8%, p < 0.001 respectively, n = 10). 
(F) In the presence of glycolytic inhibitors, the protection of pUL37 × 1 over-expression against 30 μM 
6-OHDA, 48 hours treatment was still significant but attenuated (pUL37 × 1: 11.7 ± 1.2%, pUL37 × 1 + 10 μM 
2DG: 17.8 ± 1.3%, pUL37 × 1 + 5 μM 3BP: 18.0 ± 1.6%, p < 0.01 respectively, n = 6). Data were presented as 
mean ± S.E.M. Statistics was performed by either one-ANOVA with Dunnett’s post-hoc analysis or Student’s 
t-test. (N.S., non-significant, *p < 0.05, **p < 0.01, ***p < 0.001).
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Discussion
The present study demonstrated the neuroprotective effect of pUL37 × 1 over-expression against staurosporin 
and 6-OHDA-induced apoptosis and cell death in both SH-SY5Y and primary rat cortical cultured cells. This 
protective effect of pUL37 × 1 appears to be mediated through two separate mechanisms, both of which mod-
ulate mitochondria-dependent apoptosis. pUL37 × 1, located on the mitochondrial outer membrane, led to the 
mitochondrial translocation and inactivation of Bax. The second mechanism involved mitochondrial hyperpolar-
ization with increased calcium release and enhanced PFK-mediated glycolysis and hyperpolarization. Cell death 
protection was attenuated with inhibitors of glycolysis and of calcium release (summary in Fig. 7). The strategy of 
using viral derived proteins as a means to target mitochondria for neuroprotection has recently been supported 
by using a protein derived from Borna disease virus17and the β-2.7 RNA from CMV18.
The advantages of using stable pUL37 × 1 over-expressing lines instead of transient transfection include 
long-term gene expression, consistency and the option of further genetic manipulation19. After antibiotic selec-
tion and pUL37 × 1-HA expression confirmation by western blot analysis, we selected three lines in order to 
eliminate the impact of possible cloning artefacts. All three lines presented a homogenous pUL37 × 1-HA expres-
sion by immunocytochemistry, which also confirmed the mitochondrial localization of pUL37 × 1 in SH-SY5Y 
cells. This has been reported previously in HeLa cells20 and the first domain of pUL37 × 1 has been identified as 
responsible for mitochondria targeting and localization21.
The release of cytochrome c from mitochondria to cytoplasm results from mitochondrial membrane per-
meabilization (MMP), is a point-of-no-return in apoptosis. Cytoplasmic cytochrome c interacts with Apaf-1 
protein to form an apoptosome and activates caspase. Hence, both the release of cytochrome c and the acti-
vation of caspase, especially caspase-3, are the hallmarks of apoptosis processing22. pUL37 × 1 over-expression 
Figure 6. That pUL37 × 1 increased glycolysis was dependent to intracellular calcium. (A,B) Representative 
western blot and densitometry analysis revealed that pUL37 × 1 over-expression did not alter the protein level 
of certain key glycolytic enzymes, including hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase 
(PFK) and pyruvate kinase (PK) on SH-SY5Y cells. The expression level was corrected by the level of β-actin, 
which served as a loading control (n = 3). (C) pUL37 × 1 over-expression increased phosphofructokinase 
(PFK) activity. (pUL37 × 1: 158.4 ± 22.4, control: 121.0 ± 9.9 units/μg, n = 6) (D) pUL37 × 1 over-expression 
increased intracellular and mitochondrial calcium. The net fluorescence unit (FU) of Fluo-4 and Rhod-2 were 
higher in pUL37 × 1 over-expressing cells compared with control (FU of Fluo-4: control :54.5 ± 6.2, pUL37 × 1: 
76.4 ± 8.5; FU of Rhod-2: control: 54.1 ± 9.0, pUL37 × 1: 83.4 ± 8.6). (E) Upon 30 nM BAPTA-AM treatment, 
the glycolytic activity of pUL37 × 1 over-expressing cells was significantly lower than control at 37.5 (control: 
120.2 ± 7.5%, pUL37 × 1:95.1 ± 9.3%), 45 (control: 111.5 ± 9.9%, pUL37 × 1:83.8 ± 8.0%), and 52.5 (control: 
102.3 ± 9.7%, pUL37 × 1:72.1 ± 6.6%) minutes time point. n = 4. The glycolytic activity was normalized by basal 
glycolytic activity from each group (pUL37 × 1 and control). Data were presented as mean ± S.E.M. Statistics 
was performed by two-tailed Student’s t- test. (N.S., non-significant, *p < 0.05).
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in SH-SY5Y and primary rat cortical cells reduced the release of cytochrome c and activation of caspase-3 and 
decreased cell death upon staurosporin and 6-OHDA treatment. It is still important to measure cell death pro-
tection after confirmation of anti-apoptotic effect because in some occasions, down-regulation of apoptosis can 
promote necrosis23,24. In SH-SY5Y cells, the protection was present under several different conditions, including 
high dose, short-term toxin treatment and moderate dose, longer-term toxin treatment. These results indicate 
that pUL37 × 1 is anti-apoptotic in neuronal cells and neuroprotective in cellular models.
Bax, a pro-apoptotic bcl-2 family protein, is thought to play an important role in apoptotic neuronal death in 
PD25,26. Bax ablation has been demonstrated to have an anti-apoptotic and neuroprotective effect. Vila et al. show 
that Bax deficient mutant mice were resistant to MPTP neurotoxicity27. In the present study, bax siRNA silencing 
reduced Bax protein expression levels and resulted in cell death protection against staurosporin in control cells. 
However, silencing of bax in pUL37 × 1 over-expressing cells did not provide further cell death protection against 
staurosporin compared with pUL37 × 1 expressing cells. Failure of cell death protection by bax siRNA silencing 
in pUL37 × 1 over-expressing cells indicated a Bax-dependent neuroprotective mechanism of pUL37 × 1, which 
support the Bax inactivation effect of pUL37 × 1 from previous reports5–7.
Mitochondria can become hyperpolarized due to the reverse of proton trafficking through complex V. When 
the intracellular ATP is sufficient, complex V consumes ATP to pump protons out rather than in. The main source 
of extra-mitochondrial ATP generation is glycolysis. Glycolysis is an alternative energy resource to oxidative 
phosphorylation, and though it might be seen as bioenergetically inefficient, due to low ATP and NADP yield, 
because of its fast reaction rate, glycolysis is able to provide sufficient energy to meet cellular demand28. Cancer 
cells are thought to generate ATP predominantly from glycolysis even in oxygen-rich conditions, the Warburg 
effect29. Owing to this alteration of glucose metabolism, cancer cells usually contain hyperpolarized mitochon-
dria and are less sensitive to apoptosis30–32. Cells with higher glycolytic capacity, such as astrocytes and myocytes, 
also utilize glycolysis to protect cell death by enhancing mitochondrial membrane potential33,34. In in vitro PD 
models, higher glycolysis activity contributed to neuroprotection against MPTP35–37. We have demonstrated a 
novel protective effect of pUL37 × 1 that is mediated via the enhancement of glycolysis and leads to the hyper-
polarization of the mitochondrial membrane potential. Glycolytic inhibitors attenuated the hyperpolarization 
and protective effects of pUL37 × 1 over-expression. Mitochondrial hyperpolarization also resulted in reduced 
cytosolic cytochrome c level in the absence of toxin. In physiological status, cytochrome c is loosely attached to 
the mitochondrial inner membrane due to the presence of mitochondrial membrane potential. Hyperpolarization 
of mitochondrial membrane potential enhances the binding affinity and reduce the leakage of cytochrome c to 
the cytoplasm38,39.
Glycolysis is tightly regulated at several stages and PFK is the most crucial control point in the glycolytic pathway. 
The enzymatic activity is tightly regulated by the ATP/AMP ratio, citrate, and fructose-2,6-bisphosphate. 
Intracellular calcium also plays an important role in the activity of PFK: high intracellular calcium leads to the 
binding of calmodulin to the high-affinity site of PFK monomer and stabilizes the PFK dimeric form with full 
activity15. MPTP-treated monkeys demonstrated a decrease of the enzyme activities related to the glycolytic path-
way, especially the decrease in PFK40. It has been postulated that CMV infection increases glycolysis by activa-
tion of the calmodulin-dependent pathway41 and pUL37 × 1 is essential for this biogenergetic effect because it 
triggers the release of calcium storage from the ER16. In the present study, pUL37 × 1 over-expression did not 
alter the expression level of PFK and other glycolytic enzymes, but did increase PFK activity. Moreover, calcium 
caging by BAPTA-AM attenuated the increased glycolytic capacity of pUL37 × 1, which also supports the role of 
calcium-dependent increased glycolysis. It is known that alteration of intracellular Ca2+ is related to apoptosis. 
Also known is that Ca2+ content in ER determines the sensitivity to apoptotic stimuli42–43. Dysregulated Ca2+ 
signalling is considered as a contributing factor in the pathogenesis of PD44, in which the specific involvement 
Figure 7. Summary of dual anti-apoptotic effects of pUL37 × 1. In the present study, we demonstrated that 
pUL37 × 1 over-expression protected apoptotic death through two pathways: one protective mechanism of 
pUL37 × 1 depended on Bax inactivation and the other was due to mitochondrial hyperpolarization. pUL37 × 1 
over-expression induced the increased intracellular calcium, which activated phosphofructokinase (PFK) and 
up-regulated glycolysis, followed by mitochondrial hyperpolarization.
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of calpain has been investigated in toxin-induced PD models45–47. Any role of pUL37 × 1 in Ca2+ homeostasis 
remains uncertain.
The usage of two toxins, staurosporine and 6-OHDA in the present study, serves different purposes. 
Staurosporine is protein kinase c inhibitor and a strong apoptosis inducer as well. It triggers remarkable mito-
chondrial depolarization and Bax translocalization48. The protection of pUL37 × 1 against staurosporine-induced 
neuronal apoptotic death confirmed that pUL37 × 1 is able to be neuroprotective through anti-apoptosis. 
6-OHDA is served to provide a PD in vitro model, which induced both apoptosis and necrosis though excessive 
oxidative stress49–51. pUL37 × 1 reduced not only caspase-3 activation but also total cell death, which reflect the 
summation of apoptosis and necrosis.
In conclusion, the mitochondrial mechanisms by which pUL37 × 1 inhibits apoptosis and prevents cell death 
may serve as a model for potential neuroprotective therapies that involve mitochondrial pathways.
Material and Methods
Cells and plasmids. SH-SY5Y cells were maintained as previous descriptions52 with reagents supplied from 
Life Technologies (Paisley, UK). The method for setting up E18 primary rat cortical culture was adapted from pre-
vious well-established protocols53, and they were used 7 days post-culture. pul37 × 1 open reading frame (coding 
sequence complement joining 50262..51197,51302..51344,52573..53060; Genbank accession NC_006273) added 
with a 3′ haemagluttinin (HA) epitope (total reading frame length 1494 nucleotides) was cloned into pcDNA3.1 
plasmid. Stable ectopic expression was established in SH-SY5Y cells.
Protein assay. Whole cell lysates for Western blot analysis were prepared in 10 mM Tris–HCl pH 7.5, 0.1% of 
SDS and in the presence of protease inhibitors (Fisher Scientific, Loughborough, UK), followed by DNAseI diges-
tion (Promega, Southampton, UK). Protein samples were separated under reducing conditions by SDS-PAGE 
using the Novex system (Life Technologies), transferred to PVDF (Millipore, Watford, UK ) and were analyzed 
by a standard Western blot protocol using Amersham ECL Western Blotting Detection Reagent and Amersham 
Hyperfilm (GE Healthcare, Little Chalfont, UK). The following antibodies were used: anti-HA epitope antibody 
(clone 16B12, Life Technologies), anti-β-actin antibody (Abcam, Cambridge, UK), anti-Bax (NT) antibody 
(Millipore), anti-phosphofructokinase antibody, anti-pyruvate kinase antibody, and hexokinase 1 and 2 antibody 
(New England Biolabs, Hitchin, UK ). Protein concentration was decided by bicinchoninic acid assay (BCA) 
according to manufacturer’s instructions (Fisher Scientific).
Immunocytochemistry and confocal microscopy. For immunocytochemistry, cells were fixed with 
4% paraformaldehyde in phosphate buffered solution (PBS), permeabilized by adding cold methanol, and then 
processed in succession with a primary antibody, either anti-HA epitope antibody (Cambridge Bioscience, 
Cambridge,UK), anti-TOM20 antibody (Santa Cruz) or anti-Bax (NT) antibody (Millipore), Alexa Fluor second-
ary antibody (Life Technologies), and mounted with Citifluor (London, UK) in the presence of DAPI. Fluorescent 
images were obtained by epifluorescent microscope. In order to obtain image slices <1.5 μm, a Zeiss 510 laser 
scanning microscope was used.
Apoptosis and cell death assay. Cytochrome c ELISA was performed according to manufacturer’s 
instructions ( Life Technologies). Cells were lysed by a buffer containing 10 mM Tris, pH 7.4, 100 mM NaCl, 
1 mM EDTA, 1 mM EGTA, and 10% glycerol incubated for 10 minutes. Cytosolic fraction was separated by a 
centrifugation at 12,000× g at 4 °C for 10 minutes. Caspase-3 activity was measured from cell lysates accord-
ing to the manufacturer’s instruction of the EnzChek® Caspase-3 Assay Kit #2 (Life Technologies) which has 
been described previously54. Apoptotic neurons in primary rat cortical culture were identified by anti-cleaved 
caspase-3 antibody (New England Biolabs). Apoptosis was induced by 20 μM 6-OHDA treatment for 6 hours 
and followed by the aforementioned immunocytochemistry protocols. LDH release assay (Roche, Burgess Hill, 
UK) was used to quantify the cell death and the protocols had been described55. PI staining was used to dis-
tinguish between live and dead cells. Both cell death measurements are based on similar principle: the ratio of 
LDH release/PI fluorescence between experiments to Triton X-100 treated control would be recognized as the 
percentage of cell death. For the detection of neuronal death in primary culture, cells were stained with 0.001% 
Fluoro-Jade C (Millipore) after fixed with 4% paraformaldehyde. Positive stained cells were counted under by 
epifluorescent microscope. The count of the death/apoptosis neurons is made under blinded condition. For each 
cover slips, 8–10 fields were selected. The number of RFP expressed cells with positive FJ-C or cleaved caspase-3 
stain divided by the total number of RFP expressed cells was the percentage of death/apoptosis.
siRNA silencing. 105 SH-SY5Y cells suspended in 500 μl growth medium were incubated with 6 nM siRNA 
(Dharmacon, GE Health) and 4.5 μl of HiPerFect transfection reagent (Qiagen, Manchester, UK) at 37 °C/5% CO2 
for 24 hours. The efficiency of silencing was confirmed by Western blot analysis.
Mitochondrial membrane potential measured by Tetramethylrhodamine, methyl ester(TMRM). 
Steady stable mitochondrial TMRM (Life Technologies) fluorescence was measured from confocal images as 
previously described56,57. Images were analyzed by ImageJ software (National Institutes of Health, Maryland, U.S.) 
following protocols of analysis that have been previously described58.
OCR and extracellular acidification rate (ECAR). OCR and ECAR were measured by the XF extracel-
lular flux analyzer following manufacturer’s instructions (Seahorse Bioscience, MA, US). For measuring OCR, 
25 mM glucose, 1 μg/ml oligomycin and 2 μM rotenone were loading sequentially whereas for ECAR, 25 mM 
glucose, 1 μg/ml oligomycin and 100 μM 2DG were applied. 30 nM BAPTA-AM (Life Technologies) which was 
used to cage intracellular calcium was applied in ECAR measurement after glucose addition.
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PFK assay. PFK enzymatic activity was measured according to manufacturer’s protocols (Sigma–Aldrich, 
Dorset, UK).
ADP phosphorylation ability and mitochondrial respiratory chain complex enzymatic activity 
measurement. The measurement of ADP phosphorylation ability and respiratory chain complex enzymatic 
activity had been described by Gegg et al.59. Enzymatic activity was measured by spectrophotometric methods 
and ADP phosphorylation was measured by ATP Bioluminesence Assay kit HSII.
Intracellular and mitochondrial calcium measurement. Cells were incubated with 5 ng/ml of 
Fluo-4 FF, AM and Rhod-2, AM (Life Technologies) in standard HBSS in the presence of 0.0025% Pluronic 
for 30 minutes at room temperature, followed by another incubation in HBSS alone for another 30 minutes. 
Steady-state confocal images were obtained using a Zeiss 510 laser scanning microscope, to calculate the average 
net fluorescence after background subtraction. Fluo-4 and Rhod-2 were excited at 48 nm and 543 nm respectively.
Statistics. All data were presented as mean ± standard error of mean (S.E.M.). Statistics was performed by 
either two-tailed Student’s t- test or one-way ANOVA with post-hoc analysis. p value less than 0.05 is recognized 
as significant.
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